Advaxis Appoints Thomas A. Moore to Its Board of Directors; Todd Derbin Resigns as Chairman of the Board.

NORTH BRUNSWICK, N.J. -- Advaxis (OTCBB: ADXS) has appointed Thomas A. Moore, former President and Chief Executive Officer of Nelson Communications, Inc., Biopure Corporation and Proctor & Gamble veteran to its Board of Directors.

Mr. Moore is currently a private investor with broad experience in general management and healthcare.

Moore has had a 23-year career with the Procter & Gamble Company in multiple managerial positions, including President of Health Care Products where he was responsible for prescription and over-the-counter medications worldwide, and Group Vice President of the Procter & Gamble Company. In this role, he was responsible for over $3 billion of worldwide healthcare sales in both over-the-counter and prescription drugs in over one hundred countries and an annual research and development budget in excess of $200 million.

In 1996, Mr. Moore moved to privately held Nelson Communications, Inc., a growing company in the medical communications sector, as President and CEO. In November 2000, after revenues had more than tripled over four years, Nelson Communications was sold to the Publicis Groupe, the fourth largest advertising group worldwide, for just under $250 million. Mr. Moore was appointed President of Nelson Communications Worldwide, managing the worldwide healthcare marketing assets of the Publicis Groupe.

Recently, Moore was President and Chief Executive Officer of Biopure Corporation, a developer of oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues.

"It is an honor to have a man of Moore's caliber on our Board of Directors. His expertise and experience in the healthcare sector, as well as in sales and marketing, will be invaluable to the continued growth of the Company, especially as we examine and pursue strategic opportunities while progressing our cancer vaccines through the clinic," said Advaxis President and Chief Executive Officer Roni Appel.

Mr. Moore said: "Advaxis with its patented Listeria-based technology has enormous potential, I believe, in the fight against cancer. I look forward to working with such an enthusiastic team of high caliber scientists."

A graduate of Princeton University, Moore currently serves as a Board member for Alteon, a publicly traded developer of novel drugs designed to reverse certain effects of aging, El Dorado, a targeted marketer to unassimilated Hispanics, Medmeme that measures Medical Education effectiveness, and Opt-e-scrip, which markets a clinical system to compare multiple drugs in the same patient. He also serves as Chairman at Mayan Pigments, which has developed and patented Mayan pigment technology.

The Company's Chairman of the Board, Todd Derbin, submitted his resignation effective September 7, 2006 due to personal commitments and obligations.

About Advaxis

Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis is entering a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.